Pharmacy News

  • ChinaBio® Partnering Forum 2012 In Suzhou Brings Big Pharma Companies to China
    CARLSBAD, Calif. & SUZHOU, China–(BUSINESS WIRE)–The international biotech and pharma community will converge upon the city of Suzhou, China, a rapidly growing base for life science industries, at ChinaBio® Partnering Forum 2012 on May 23 & 24.
  • PerkinElmer Announces Agreement with Macrogen, Inc. to Provide Next Generation Sequencing Solutions
    WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., today announced an agreement to provide Next Generation Sequencing (NGS) sample preparation solutions to Macrogen, Inc., a Korean-based global sequencing company.
  • Baxter Declares Quarterly Dividend
    DEERFIELD, Ill.–(BUSINESS WIRE)–The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.335 per Baxter common share. The dividend is payable on July 2, 2012 to shareholders of record as of June 8, 2012. Over the last five years, Baxter has consistently grown its dividends for shareholders, more than doubling the rate during this period. In total, the company has returned approximately $11.4 billion to shareholders over the last five years in the
  • Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth
    SEATTLE–(BUSINESS WIRE)–May 7, 2012–Dendreon Corporation (Nasdaq:DNDN) today reported results for the quarter ended March 31, 2012. Net product revenue for the quarter was $82.0 million compared to $27.0 million for the quarter ended March 31, 2011. Net loss in the first quarter of 2012 was $103.9 million or $0.70 per share, compared to a net loss of $112.8 million, or $0.78 per share, for the same period in 2011. The current period results include approximately $17 million in cash and non-ca
  • Charles River to Present at May Conferences
    WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Baird 2012 Growth Stock Conference in Chicago, Illinois on Wednesday, May 9th, at 10:05 a.m. CDT (11:05 a.m. EDT), and the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas, Nevada on Tuesday, May 15th, at 1:40 p.m. PDT (4:40 p.m. EDT). Management will present an overview of Charles River’s strategic focus and business developments. A liv
  • Codexis to Participate in Upcoming Investor Conferences
    REDWOOD CITY, Calif.–(BUSINESS WIRE)–Codexis, Inc. (NASDAQ:CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the company will be participating in the following upcoming investor conferences: JMP Securities 11th Annual Research ConferenceDate: Monday, May 14thTime: 8:30am PTLocation: San Francisco, CASpeaker: Peter Strumph, Interim CEO Deutsche Bank 2012 Clean Tech, Utilities & Power Co
  • Maxygen Reports First Quarter 2012 Financial Results
    SAN MATEO, Calif.–(BUSINESS WIRE)–Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2012. First Quarter 2012 Financial Results Maxygen reported a net loss attributable to Maxygen, Inc. of $2.6 million, or $0.09 per basic and diluted share, for the first quarter of 2012, compared to net income attributable to Maxygen, Inc. of $1.5 million, or $0.05 per basic and diluted share, for the same period in 2011. Tot
  • Salix Pharmaceuticals Reports 1Q2012 Results
    RALEIGH, N.C.–(BUSINESS WIRE)–Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates. Total product revenue was $171.1 million for the first quarter of 2012, a 62% increase compared to $105.9 million for the first quarter of 2011. XIFAXAN® revenue for the first quarter of 2012 was $112.9 million, a 40% increase compared to $80.7 million for the first quarter of 2011. APRISO® revenue for the
  • Affymax Reports First Quarter 2012 Financial Results
    PALO ALTO, Calif.–(BUSINESS WIRE)–Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2012. The net income for the first quarter of 2012 was $31.5 million (or $0.87 per share) compared to a net loss of $9.6 million (or $(0.36) per share) for the first quarter of 2011. Affymax recognized total revenue for the quarter ended March 31, 2012, of $63.2 million compared to $16.7 million for the quarter ended March 31, 2011. The increase in revenue was t

Digest powered by RSS Digest


Advertisement

Leave a Reply